You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.
This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.
Supporting healthy eating patterns is fundamental in diabetes treatment, with management of dietary quality and energy restriction being core dimensions for improving glycemic control.
Applying a person-centered approach to identify healthy dietary habits can help patients achieve a new energy deficit, leading to weight loss and additional health benefits.1
Significant improvements to HbA1c and cardiometabolic health can be achieved by increasing physical activity level.
Patients should be encouraged to ≥150 min of moderate-intensity physical activity or ≥75 min vigorous-intensity activity per week, but an increase of as little as 500 steps a day can decrease the all-cause mortality rates and risk of cardiovascular morbidity with 2-9%.1
People living with type 2 diabetes often suffer from sleep disorders, which are associated with an increased risk of obesity and impairments in daily functioning. Studies show that more than half of people living with type 2 diabetes are affected by obstructive sleep apnea, which is associated with blood glucose levels.1
Still not under control?
Scroll down to see recommendations for glucose-lowering medications when patients are not controlled through diet and exercise management.
Still not under control?
Scroll down to see recommendations for glucose-lowering medications when patients are not controlled through diet and exercise management.
Oral tablet or injection
*according to label indication
Oral tablet
*according to label indication
Oral tablet or injection
*according to label indication
Oral tablet
*according to label indication
Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-2786.
Buse JB, Wexler D, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.
Mosenzon O, Alguwaihes A , Leon JLA et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154.